JP7618597B2 - D1ポジティブアロステリックモジュレーターとしての置換されたテトラヒドロイソキノリン誘導体 - Google Patents

D1ポジティブアロステリックモジュレーターとしての置換されたテトラヒドロイソキノリン誘導体 Download PDF

Info

Publication number
JP7618597B2
JP7618597B2 JP2021575050A JP2021575050A JP7618597B2 JP 7618597 B2 JP7618597 B2 JP 7618597B2 JP 2021575050 A JP2021575050 A JP 2021575050A JP 2021575050 A JP2021575050 A JP 2021575050A JP 7618597 B2 JP7618597 B2 JP 7618597B2
Authority
JP
Japan
Prior art keywords
formula
compound
methyl
pharma
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021575050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537994A5 (cg-RX-API-DMAC7.html
JP2022537994A (ja
Inventor
ヴァレーデ、アンヌ
Original Assignee
ユーシービー バイオファルマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシービー バイオファルマ エスアールエル filed Critical ユーシービー バイオファルマ エスアールエル
Publication of JP2022537994A publication Critical patent/JP2022537994A/ja
Publication of JP2022537994A5 publication Critical patent/JP2022537994A5/ja
Application granted granted Critical
Publication of JP7618597B2 publication Critical patent/JP7618597B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021575050A 2019-07-01 2020-06-29 D1ポジティブアロステリックモジュレーターとしての置換されたテトラヒドロイソキノリン誘導体 Active JP7618597B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183641.0 2019-07-01
EP19183641 2019-07-01
PCT/EP2020/068181 WO2021001286A1 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Publications (3)

Publication Number Publication Date
JP2022537994A JP2022537994A (ja) 2022-08-31
JP2022537994A5 JP2022537994A5 (cg-RX-API-DMAC7.html) 2023-07-04
JP7618597B2 true JP7618597B2 (ja) 2025-01-21

Family

ID=67137842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575050A Active JP7618597B2 (ja) 2019-07-01 2020-06-29 D1ポジティブアロステリックモジュレーターとしての置換されたテトラヒドロイソキノリン誘導体

Country Status (28)

Country Link
US (1) US12358890B2 (cg-RX-API-DMAC7.html)
EP (1) EP3993795B1 (cg-RX-API-DMAC7.html)
JP (1) JP7618597B2 (cg-RX-API-DMAC7.html)
KR (1) KR102949226B1 (cg-RX-API-DMAC7.html)
CN (1) CN114008032B (cg-RX-API-DMAC7.html)
AR (1) AR119317A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020299705B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021022379A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139622A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002949A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017740A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22007557A (cg-RX-API-DMAC7.html)
ES (1) ES3069145T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260599T1 (cg-RX-API-DMAC7.html)
IL (1) IL289317B2 (cg-RX-API-DMAC7.html)
MA (1) MA56445B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021015872A (cg-RX-API-DMAC7.html)
MY (1) MY210362A (cg-RX-API-DMAC7.html)
PE (1) PE20220373A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552819A1 (cg-RX-API-DMAC7.html)
PL (1) PL3993795T3 (cg-RX-API-DMAC7.html)
RS (1) RS68243B1 (cg-RX-API-DMAC7.html)
SA (1) SA521431274B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112539XA (cg-RX-API-DMAC7.html)
TW (1) TWI842923B (cg-RX-API-DMAC7.html)
UA (1) UA130613C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021001286A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202109194B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020131671A1 (en) 2018-12-18 2020-06-25 Eli Lilly And Company Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
EP4200280B1 (en) 2020-10-07 2024-02-21 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
CN117337173A (zh) * 2021-03-09 2024-01-02 伊莱利利公司 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017530185A (ja) 2014-10-08 2017-10-12 ユーシービー バイオファルマ エスピーアールエル テトラヒドロイソキノリン誘導体
JP2019513792A (ja) 2016-04-13 2019-05-30 ユーシービー バイオファルマ エスピーアールエル テトラヒドロイソキノリン誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520217A (ja) 2007-03-01 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンh3受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
US9278960B2 (en) 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
EP3596060B1 (en) * 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017530185A (ja) 2014-10-08 2017-10-12 ユーシービー バイオファルマ エスピーアールエル テトラヒドロイソキノリン誘導体
JP2019513792A (ja) 2016-04-13 2019-05-30 ユーシービー バイオファルマ エスピーアールエル テトラヒドロイソキノリン誘導体

Also Published As

Publication number Publication date
BR112021022379A2 (pt) 2022-03-08
AU2020299705B2 (en) 2026-03-19
US12358890B2 (en) 2025-07-15
CN114008032B (zh) 2023-11-10
AU2020299705A1 (en) 2021-12-09
IL289317B2 (en) 2025-09-01
SA521431274B1 (ar) 2024-01-09
US20220251064A1 (en) 2022-08-11
CO2021017740A2 (es) 2022-01-17
IL289317A (en) 2022-02-01
KR20220029687A (ko) 2022-03-08
MX2021015872A (es) 2022-02-03
EP3993795A1 (en) 2022-05-11
TW202115009A (zh) 2021-04-16
SG11202112539XA (en) 2021-12-30
IL289317B1 (en) 2025-05-01
TWI842923B (zh) 2024-05-21
AR119317A1 (es) 2021-12-09
ZA202109194B (en) 2023-11-29
KR102949226B1 (ko) 2026-04-06
CA3139622A1 (en) 2021-01-07
PE20220373A1 (es) 2022-03-16
MA56445B1 (fr) 2026-05-26
ECSP22007557A (es) 2022-02-25
PH12021552819A1 (en) 2022-09-28
CL2021002949A1 (es) 2022-07-15
HRP20260599T1 (hr) 2026-06-05
CN114008032A (zh) 2022-02-01
MA56445A (fr) 2022-05-11
UA130613C2 (uk) 2026-04-01
MY210362A (en) 2025-09-13
PL3993795T3 (pl) 2026-07-20
EP3993795C0 (en) 2026-04-22
EP3993795B1 (en) 2026-04-22
WO2021001286A1 (en) 2021-01-07
ES3069145T3 (en) 2026-06-04
RS68243B1 (en) 2026-07-31
JP2022537994A (ja) 2022-08-31

Similar Documents

Publication Publication Date Title
JP7510444B2 (ja) D1ポジティブアロステリックモジュレーターとしての置換テトラヒドロイソキノリン誘導体
EP3442945B1 (en) Tetrahydroisoquinoline derivatives
EA035544B1 (ru) Производные тетрагидроизохинолина
US12358890B2 (en) Substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator
JP2023554033A (ja) ジヒドロイソキノリニル誘導体
RU2824527C2 (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
JP2023551173A (ja) オクタヒドロイソキノリニル誘導体
KR20230121849A (ko) D1 포지티브 알로스테릭 모듈레이터로서 치환된 테트라하이드로이소퀴놀린유도체
HK40060812B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
HK40060812A (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
RU2824581C2 (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
HK40058931B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
HK40058931A (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250108

R150 Certificate of patent or registration of utility model

Ref document number: 7618597

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150